Biogen Wins Approval for Long-Lasting Hemophilia B Treatment

Biogen Idec Inc., a biotechnology company that specializes in multiple sclerosis treatments, won U.S. approval for a long-lasting hemophilia B drug that may reduce the need for infusions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.